Xin Du

3.0k total citations · 1 hit paper
74 papers, 1.8k citations indexed

About

Xin Du is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Xin Du has authored 74 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Hematology, 28 papers in Genetics and 21 papers in Molecular Biology. Recurrent topics in Xin Du's work include Acute Myeloid Leukemia Research (25 papers), Mesenchymal stem cell research (14 papers) and CAR-T cell therapy research (13 papers). Xin Du is often cited by papers focused on Acute Myeloid Leukemia Research (25 papers), Mesenchymal stem cell research (14 papers) and CAR-T cell therapy research (13 papers). Xin Du collaborates with scholars based in China, United States and Malaysia. Xin Du's co-authors include Jianyu Weng, Peilong Lai, Duanqing Pei, Chang He, Tian Zhou, Zenan Yuan, Suxia Geng, Liyan Guo, Yangqiu Li and Xiaomei Chen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Scientific Reports.

In The Last Decade

Xin Du

65 papers receiving 1.8k citations

Hit Papers

Challenges and advances in clinical applications of mesen... 2021 2026 2022 2024 2021 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xin Du China 20 849 539 512 449 314 74 1.8k
Jianyu Weng China 19 836 1.0× 681 1.3× 507 1.0× 519 1.2× 308 1.0× 84 2.1k
Peilong Lai China 15 716 0.8× 452 0.8× 286 0.6× 265 0.6× 258 0.8× 52 1.4k
Rebekka Wehner Germany 27 652 0.8× 507 0.9× 941 1.8× 990 2.2× 227 0.7× 66 2.2k
Marta Serafini Italy 23 675 0.8× 509 0.9× 476 0.9× 315 0.7× 121 0.4× 67 1.8k
Fabrizio Vianello Italy 18 520 0.6× 408 0.8× 901 1.8× 801 1.8× 249 0.8× 89 2.2k
Shyam A. Patel United States 16 428 0.5× 477 0.9× 406 0.8× 233 0.5× 193 0.6× 61 1.1k
Olli Tynninen Finland 24 710 0.8× 496 0.9× 460 0.9× 340 0.8× 327 1.0× 64 2.0k
Jérôme Amiaud France 24 685 0.8× 210 0.4× 462 0.9× 496 1.1× 206 0.7× 48 1.8k
Kazuya Sato Japan 17 533 0.6× 951 1.8× 356 0.7× 410 0.9× 146 0.5× 78 2.0k
Enrique J. Andreu Spain 26 896 1.1× 1.1k 2.0× 398 0.8× 276 0.6× 192 0.6× 46 2.4k

Countries citing papers authored by Xin Du

Since Specialization
Citations

This map shows the geographic impact of Xin Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xin Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xin Du more than expected).

Fields of papers citing papers by Xin Du

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xin Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xin Du. The network helps show where Xin Du may publish in the future.

Co-authorship network of co-authors of Xin Du

This figure shows the co-authorship network connecting the top 25 collaborators of Xin Du. A scholar is included among the top collaborators of Xin Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xin Du. Xin Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Yong, Xin Du, Wei Yang, & Guangyu Zhang. (2025). Disparities in dynamic green exposure across residents’ mobility patterns: A case study in Chengdu. Urban forestry & urban greening. 112. 128978–128978. 2 indexed citations
3.
Wang, Jianxiang, Bin Jiang, Li J, et al.. (2024). Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. Leukemia. 38(11). 2410–2418. 2 indexed citations
4.
Yang, Yong, et al.. (2024). Case report: a rare case of intradural and pleural wall cystic echinococcosis. BMC Infectious Diseases. 24(1). 980–980.
5.
Yu, Yang, Adam Cooper, Jermaine Coward, et al.. (2024). 478O Updated results of oral PD-L1 inhibitor ABSK043 in advanced solid tumor patients (pts) from a phase I study. Annals of Oncology. 35. S1580–S1580.
6.
Wu, Miao, Yawen Wang, Yulian Wang, et al.. (2023). Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-β-SMAD2/3 pathway. Molecular Medicine. 29(1). 59–59. 14 indexed citations
7.
Chen, Buxin, et al.. (2023). Novel Anti-TMPRSS6 Monoclonal Antibody Provides a Potential Therapeutic Approach for the Treatment of Polycythemia Vera. Blood. 142(Supplement 1). 3837–3837. 1 indexed citations
8.
Wang, Yubin, et al.. (2023). A novel anti‐amyloid‐beta oligomer antibody reduces plaque burden and slows cognitive decline in 5xFAD mice. Alzheimer s & Dementia. 19(S21). 1 indexed citations
9.
Wang, Jinghua, Weida Wang, Hao Chen, et al.. (2021). C‐Type Lectin‐Like Molecule‐1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study. BioMed Research International. 2021(1). 6643948–6643948. 12 indexed citations
10.
Wang, Jianxiang, Bin Jiang, Li J, et al.. (2021). Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia. Blood. 138(Supplement 1). 695–695. 5 indexed citations
11.
Huang, Xin, Cunte Chen, Suxia Geng, et al.. (2021). Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome. Biomarker Research. 9(1). 46–46. 8 indexed citations
12.
Chen, Xiaofang, Ningyu Li, Jianyu Weng, & Xin Du. (2021). Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies. Frontiers in Cell and Developmental Biology. 8. 617466–617466. 7 indexed citations
13.
Wang, Yang, Quan Liu, Yang Han, et al.. (2020). Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis. SHILAP Revista de lepidopterología. 1 indexed citations
14.
Luo, Chengwei, Peilong Lai, Lin Wei, et al.. (2020). von Willebrand Factor as a Predictor for Transplant-Associated Thrombotic Microangiopathy. Clinical and Applied Thrombosis/Hemostasis. 26. 2873291212–2873291212. 10 indexed citations
15.
Wang, Yulian, Peilong Lai, Xiaomei Chen, et al.. (2017). Attenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of Treg. Scientific Reports. 7(1). 3603–3603. 9 indexed citations
16.
Jin, Yanli, Danian Nie, Juan Li, et al.. (2016). Gas6/AXL Signaling Regulates Self-Renewal of Chronic Myelogenous Leukemia Stem Cells by Stabilizing β-Catenin. Clinical Cancer Research. 23(11). 2842–2855. 37 indexed citations
17.
Geng, Suxia, Jianyu Weng, Shaohua Chen, et al.. (2015). Abnormalities in the T Cell Receptor Vδ Repertoire and Foxp3 Expression in Refractory Anemia with Ringed Sideroblasts. DNA and Cell Biology. 34(9). 588–595. 2 indexed citations
18.
Du, Xin, et al.. (2012). The role of BCL11B in hematological malignancy. Experimental Hematology and Oncology. 1(1). 22–22. 40 indexed citations
19.
Xu, Fangping, Yan‐Hui Liu, Donglan Luo, et al.. (2011). [Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].. PubMed. 40(9). 616–21. 3 indexed citations
20.
Du, Xin, et al.. (2011). [Detection of methylation levels of multi-genes by real-time PCR in patients with myelodysplastic syndrome].. PubMed. 32(4). 254–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026